secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001493152-24-015531
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona receives FDA Complete Response Letter for pz-cel BLA due to CMC deficiencies
--------------------------------------------------------------------------------

- FDA CRL for pz-cel BLA cites additional CMC information needed; no clinical efficacy/safety deficiencies.
- No new clinical trials or clinical data requested by FDA for approval.
- Company expects to complete BLA resubmission with requested CMC data in Q3 2024.
- PDUFA date of May 25, 2024 will be missed due to proposed timing of data submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224015531/0001493152-24-015531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224015531/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-015531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer